We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$980M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
-0.84%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242K
AUM Growth
-$247M
(-100%)
Cap. Flow
+$20M
Cap. Flow
% of AUM
8,259.72%
Top 10 Holdings %
Top 10 Hldgs %
57.4%
Holding
86
New
15
Increased
42
Reduced
10
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$7.21M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.91M |
| 3 |
Veracyte
VCYT
|
+$5.84M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$4.65M |
| 5 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$3.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$5.42M |
| 2 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$5.38M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
+$4.81M |
| 4 |
Halozyme
HALO
|
+$2.85M |
| 5 |
Cytokinetics
CYTK
|
+$2.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.36% |
| 2 | Financials | 1.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IPHA
76
Innate Pharma
IPHA
$164M
| – | – |
-184,046
| Closed | -$839K |
|
77
Kura Oncology
KURA
$800M
| – | – |
-66,812
| Closed | -$935K |
|
78
MoonLake Immunotherapeutics
MLTX
$1.57B
| – | – |
-131,823
| Closed | -$1.3M |
|
79
ProKidney
PROK
$316M
| – | – |
-123,862
| Closed | -$1.23M |
|
80
VistaGen Therapeutics
VTGN
$9.89M
| – | – |
-14,139
| Closed | -$827K |
|
|
AKLI
81
DELISTED
Akili Inc
AKLI
| – | – |
-123,862
| Closed | -$1.23M |
|
|
DCPH
82
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – |
-160,526
| Closed | -$1.57M |
|
|
DNAD
83
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
| – | – |
-123,862
| Closed | -$1.22M |
|
|
DNAB
84
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
| – | – |
-123,862
| Closed | -$1.23M |
|
|
RACB
85
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| – | – |
-556,890
| Closed | -$5.42M |
|
|
INBX
86
DELISTED
Inhibrx, Inc. Common Stock
INBX
| – | – |
-24,666
| Closed | -$1.08M |
|
Similar funds
BIP
MVM
MFWP
FCM
KL
GFP
ADIC
PCM
Silverarc Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, Silverarc Capital Management held 86 positions worth $242K, down 100% from $247M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Silverarc Capital Management deployed $20M of net new capital in Q1 2022, opening 15 new positions and adding to 42 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 105,368 shares worth $5.35K.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.38M trimmed.
- Silverarc Capital Management's largest Q1 2022 buy was Apellis Pharmaceuticals: 105,368 shares worth $5.35K.
- Silverarc Capital Management added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $7.21M increase.
- Silverarc Capital Management's biggest Q1 2022 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $5.38M.
- Silverarc Capital Management fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $5.42M.
- Silverarc Capital Management's ten largest holdings make up 57% of its $242K portfolio in Q1 2022.
- Silverarc Capital Management opened 15 new positions and closed 17 in Q1 2022.
- Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $242K.
Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.